https://www.selleckchem.com/pr....oducts/17-DMAG,Hydro
This trial will test the safety and efficacy of administration of iloprost vs placebo for 72hours in trauma patients with haemorrhagic shock-induced endotheliopathy. Trial endpoints focus on the potential effect of iloprost to reduce the need for ICU stay secondary to mitigation of organ failure. SHINE-TRAUMA trial-EudraCT no. 2019-000936-24-Clinicaltrials.gov NCT03903939 Ethics Committee no. H-19014482. SHINE-TRAUMA trial-EudraCT no. 2019-000936-24-Clinicaltrials.gov NCT03903939 Ethics Committee no. H-19014482. To co
Like
Comment
Share
